Adaptive Biotechnologies Corp (NASDAQ: ADPT) on Tuesday, soared 9.40% from the previous trading day, before settling in for the closing price of $6.81. Within the past 52 weeks, ADPT’s price has moved between $2.28 and $7.46.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 21.12% annually for the last half of the decade. The company achieved an average annual earnings per share of 28.53%. With a float of $142.73 million, this company’s outstanding shares have now reached $147.56 million.
In an organization with 709 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 53.84%, operating margin of -93.9%, and the pretax margin is -110.17%.
Adaptive Biotechnologies Corp (ADPT) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adaptive Biotechnologies Corp is 3.28%, while institutional ownership is 92.27%. The most recent insider transaction that took place on Nov 18 ’24, was worth 1,235. In this transaction Chief Financial Officer of this company sold 248 shares at a rate of $4.98, taking the stock ownership to the 154,330 shares. Before that another transaction happened on Aug 22 ’24, when Company’s SVP and General Counsel sold 26,922 for $4.50, making the entire transaction worth $121,079. This insider now owns 139,365 shares in total.
Adaptive Biotechnologies Corp (ADPT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.53% per share during the next fiscal year.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators
Adaptive Biotechnologies Corp (ADPT) is currently performing well based on its current performance indicators. A quick ratio of 3.38 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.94 in one year’s time.
Technical Analysis of Adaptive Biotechnologies Corp (ADPT)
Let’s dig in a bit further. During the last 5-days, its volume was 1.69 million. That was better than the volume of 1.65 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 69.73%. Additionally, its Average True Range was 0.57.
During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 98.58%, which indicates a significant increase from 96.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 110.83% in the past 14 days, which was higher than the 86.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.12, while its 200-day Moving Average is $4.52. However, in the short run, Adaptive Biotechnologies Corp’s stock first resistance to watch stands at $7.65. Second resistance stands at $7.85. The third major resistance level sits at $8.20. If the price goes on to break the first support level at $7.10, it is likely to go to the next support level at $6.75. The third support level lies at $6.55 if the price breaches the second support level.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats
Market capitalization of the company is 1.10 billion based on 147,579K outstanding shares. Right now, sales total 170,280 K and income totals -225,250 K. The company made 46,440 K in profit during its latest quarter, and -32,070 K in sales during its previous quarter.
